Recent advancements in recanalizing therapies,i.e.,the combination of thrombolytic drugs with interventional thrombectomy,have considerably improved neurological outcome in ischemic stroke patients.Despite this progre...Recent advancements in recanalizing therapies,i.e.,the combination of thrombolytic drugs with interventional thrombectomy,have considerably improved neurological outcome in ischemic stroke patients.Despite this progress,the large majority of stroke patients still exhibit neurological deficits in the long run,and ischemic stroke continues to be the most frequent cause of long-term disability.Hence,there is an unmet need for therapies that allow enhancing neurological recovery and brain plasticity in the post-acute stroke phase(Hermann and Chopp,2012).Preclinical studies,e.g.,delivering growth factors(Reitmeir et al.,2011)or neural precursor cells(NPC)(Bacigaluppi et al.,2016),have shown that brain plasticity can be successfully stimulated in the post-acute stroke phase,resulting in functional neurological improvements.These findings raised the question whether it is possible to promote neurological recovery and brain plasticity in stroke patients.展开更多
AIM: To study the effect of S-21007, a 5-HT_3partial agonist in different animal models of anxiety inmice. METHODS: S-21007 effects were evaluatedin the behavior tests after intraperitioneal and oral acutetreatment or...AIM: To study the effect of S-21007, a 5-HT_3partial agonist in different animal models of anxiety inmice. METHODS: S-21007 effects were evaluatedin the behavior tests after intraperitioneal and oral acutetreatment or in the light/dark test after both acute andchronic treatments. RESULTS: S-21007 presentedanxiolytic-like properties after acute administration inthe light/dark box test, the mirrored chamber test, andthe elevated plus-maze at be doses 10 ng·kg^(-1)-100μg·kg^(-1), 1-100 μg·kg^(-1) and 10-100 μg·kg^(-1),respectively. In the light/dark box test, S-21007 wasactive orally after acute treatment at 100 ng·kg^(-1)-10mg·kg^(-1) and after chronic treatment (14 d) at 1-10μg·kg^(-1). S-21007 was devoid of sedative or stimula-展开更多
基金Supported by Institut de Recherches Internationales Servier,Suresnes,France and Deutsche Forschungsgemeinschaft(HE3173/3-1 and HE3173/11-1,to DMH)
文摘Recent advancements in recanalizing therapies,i.e.,the combination of thrombolytic drugs with interventional thrombectomy,have considerably improved neurological outcome in ischemic stroke patients.Despite this progress,the large majority of stroke patients still exhibit neurological deficits in the long run,and ischemic stroke continues to be the most frequent cause of long-term disability.Hence,there is an unmet need for therapies that allow enhancing neurological recovery and brain plasticity in the post-acute stroke phase(Hermann and Chopp,2012).Preclinical studies,e.g.,delivering growth factors(Reitmeir et al.,2011)or neural precursor cells(NPC)(Bacigaluppi et al.,2016),have shown that brain plasticity can be successfully stimulated in the post-acute stroke phase,resulting in functional neurological improvements.These findings raised the question whether it is possible to promote neurological recovery and brain plasticity in stroke patients.
文摘AIM: To study the effect of S-21007, a 5-HT_3partial agonist in different animal models of anxiety inmice. METHODS: S-21007 effects were evaluatedin the behavior tests after intraperitioneal and oral acutetreatment or in the light/dark test after both acute andchronic treatments. RESULTS: S-21007 presentedanxiolytic-like properties after acute administration inthe light/dark box test, the mirrored chamber test, andthe elevated plus-maze at be doses 10 ng·kg^(-1)-100μg·kg^(-1), 1-100 μg·kg^(-1) and 10-100 μg·kg^(-1),respectively. In the light/dark box test, S-21007 wasactive orally after acute treatment at 100 ng·kg^(-1)-10mg·kg^(-1) and after chronic treatment (14 d) at 1-10μg·kg^(-1). S-21007 was devoid of sedative or stimula-
